Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

Imaging Biomarkers of NAFLD, NASH, and Fibrosis

(2021) Veeral Ajmera et al.   Molecular Metabolism

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

(2021) Alessandro Mantovani et al.   Metabolites

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy

(2021) Monika Rau et al.   Expert Review of Clinical Pharmacology

Machine Learning Algorithms for Predicting Fatty Liver Disease

(2021) Xieyi Pei et al.   ANNALS OF NUTRITION AND METABOLISM

Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial

(2021) Samer Gawrieh et al.   HEPATOLOGY

Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy‐confirmed NAFLD

(2021) Gong Feng et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Non-alcoholic fatty liver disease

(2021) Elizabeth E Powell et al.   LANCET

The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments

(2021) Giovanni Targher et al.   Nature Reviews Gastroenterology & Hepatology

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

(2021) Giovanni Targher et al.   Lancet Gastroenterology & Hepatology

New drugs for NASH

(2021) Somaya A. M. Albhaisi et al.   LIVER INTERNATIONAL

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

(2021) Sven M. Francque et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

(2020) A. Mantovani et al.   DIABETES & METABOLISM

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes

(2020) Lars Johansson et al.   DIABETES OBESITY & METABOLISM

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

(2020) Lin Liu et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease

(2020) James M. Paik et al.   HEPATOLOGY

Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2020) Ling-Yun Zhang et al.   Clinics and Research in Hepatology and Gastroenterology

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

(2020) Giovanni Targher et al.   GUT

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

(2020) Olivia R Ghosh-Swaby et al.   Lancet Diabetes & Endocrinology

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

(2020) Silvina Gallo et al.   Diabetes Therapy

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

(2020) Mohammad S. Kuchay et al.   DIABETOLOGIA

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

(2020) Sven Francque et al.   Nature Reviews Gastroenterology & Hepatology

Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial

(2020) Wen Guo et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review

(2020) Zobair M. Younossi et al.   GASTROENTEROLOGY

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

(2020) Alessandro Mantovani et al.   Metabolites

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease

(2019) Joan Khoo et al.   LIVER INTERNATIONAL

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

(2019) Aino Latva-Rasku et al.   DIABETES CARE

Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

(2019) Ralph A DeFronzo et al.   Diabetes & Vascular Disease Research

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

(2019) Sabine Kahl et al.   DIABETES CARE

Thiazolidinediones: the Forgotten Diabetes Medications

(2019) Harold E. Lebovitz   Current Diabetes Reports

Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation

(2019) Maurice B. Bizino et al.   DIABETOLOGIA

Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease

(2019) Phuc Le et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy?

(2019) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study

(2019) Nikolaos Perakakis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone

(2018) Lawrence H. Young et al.   CIRCULATION

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

(2018) Fernando Bril et al.   Clinical Gastroenterology and Hepatology

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

(2018) Jan W. Eriksson et al.   DIABETOLOGIA

Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement

(2018) Frédéric Brioude et al.   Nature Reviews Endocrinology

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

(2018) Kenneth Cusi et al.   DIABETES OBESITY & METABOLISM

Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD

(2018) Jinhua Yan et al.   HEPATOLOGY

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

(2017) Michael S. Middleton et al.   GASTROENTEROLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

(2016) A. Dutour et al.   DIABETES OBESITY & METABOLISM

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

(2016) Walter N. Kernan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

(2014) Lise L Gluud et al.   BMJ Open

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY